Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Disease Reports
Leiomyosarcoma
MeSH D007890 - leiomyosarcoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D009379:
Muscle tissue neoplasms
0 Companies
0 Drugs
Success rate
D012509:
Sarcoma
23 Companies
8 Drugs
$
Success rate
D007890:
Leiomyosarcoma
2 Companies
1 Drug
$
Success rate
Events Timeline
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Johnson & Johnson
Trabectedin
Yondelis
2028-01-07
2015-10-23
Pharma Mar
Trabectedin
Yondelis
2007-09-17
Clinical Trials
Historical Success Rate
Phase 1
87
%
13/15
Phase 2
24
%
13/54
Phase 3
13
%
2/15
Approved:
1
Overall Success rate:
3%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Johnson & Johnson
Trabectedin
,
Calcium dobesilate
,
Palifosfamide
,
Anthracycline
,
Caelyx
,
Doxorubin
,
Iphosphamid
,
Hydroxydaunomycin
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use